Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer

A study on the safety and efficacy of T-DXd in combination with local radiotherapy for brain metastases in HER2-Positive and HER2-Low breast cancer patients.

Trial Details

NCT ID
NCT07117864
Phase
NA
Sponsor
QIAO LI
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • T-DXd concurrent brain radiotherapy
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Female patients aged ≥18 and ≤75 years with histologically confirmed breast cancer.
  • ECOG performance status of 0 to 2.
  • HER2-positive or HER2-low invasive breast cancer, defined as:
  • HER2-positive: IHC 3+ or IHC 2+ with FISH amplification; HER2-low: IHC 2+ without FISH amplification, or IHC 1+.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →